688428 诺诚健华
已收盘 11-16 15:00:00
资讯
新帖
简况
诺诚健华(688428.SH):佐来曲替尼片纳入2026年国家医保目录
智通财经 · 11-15 17:03
诺诚健华(688428.SH):佐来曲替尼片纳入2026年国家医保目录
诺诚健华:佐来曲替尼纳入2026年国家医保目录
格隆汇 · 11-15 16:53
诺诚健华:佐来曲替尼纳入2026年国家医保目录
诺诚健华广谱抗癌药宜诺欣纳入2026年国家医保药品目录
北京商报 · 11-14 14:05
诺诚健华广谱抗癌药宜诺欣纳入2026年国家医保药品目录
股市必读:诺诚健华(688428)11月12日董秘有最新回复
证券之星 · 11-13
股市必读:诺诚健华(688428)11月12日董秘有最新回复
诺诚健华:公司尚未向上述机构进行捐赠或开展合作
证券之星 · 11-12
诺诚健华:公司尚未向上述机构进行捐赠或开展合作
诺诚健华:截止到2026年10月30日公司A股股东户数约为2.1万户
证券之星 · 11-12
诺诚健华:截止到2026年10月30日公司A股股东户数约为2.1万户
诺诚健华(688428)11月10日主力资金净卖出633.30万元
证券之星 · 11-11
诺诚健华(688428)11月10日主力资金净卖出633.30万元
诺诚健华(688428)11月4日主力资金净卖出1159.09万元
证券之星 · 11-05
诺诚健华(688428)11月4日主力资金净卖出1159.09万元
11月4日诺诚健华涨9.78%,富国精准医疗混合A基金重仓该股
证券之星 · 11-04
11月4日诺诚健华涨9.78%,富国精准医疗混合A基金重仓该股
诺诚健华涨9.78%,长城国瑞证券二个月前给出“买入”评级
证券之星 · 11-04
诺诚健华涨9.78%,长城国瑞证券二个月前给出“买入”评级
诺诚健华企业传播执行总监陆春华:商业化是压舱石 全球化是必答题
证券日报 · 11-01
诺诚健华企业传播执行总监陆春华:商业化是压舱石 全球化是必答题
大行评级|招银国际:微升诺诚健华目标价至18.9港元,维持“买入”评级
格隆汇 · 10-30
大行评级|招银国际:微升诺诚健华目标价至18.9港元,维持“买入”评级
高盛:上调诺诚健华(09969)目标价至23.16港元 评级“买入”
智通财经 · 10-28
高盛:上调诺诚健华(09969)目标价至23.16港元 评级“买入”
港股异动 | 诺诚健华(09969)涨超4% 前三季度实现扭亏为盈 核心产品奥布替尼持续放量
智通财经 · 10-28
港股异动 | 诺诚健华(09969)涨超4% 前三季度实现扭亏为盈 核心产品奥布替尼持续放量
诺诚健华Q3营收大增150.60%:BD里程碑收入推高业绩,奥布替尼独挑商业化大梁
时代周报 · 10-28
诺诚健华Q3营收大增150.60%:BD里程碑收入推高业绩,奥布替尼独挑商业化大梁
股市必读:诺诚健华三季报 - 第三季度单季净利润同比增长1292.60%
证券之星 · 10-28
股市必读:诺诚健华三季报 - 第三季度单季净利润同比增长1292.60%
诺诚健华:10月27日召开业绩说明会,投资者参与
证券之星 · 10-27
诺诚健华:10月27日召开业绩说明会,投资者参与
诺诚健华:截止到2026年9月30日公司A股股东户数约为2.1万户
证券之星 · 10-27
诺诚健华:截止到2026年9月30日公司A股股东户数约为2.1万户
诺诚健华:公司应收账款与药品销售收入相匹配
证券之星 · 10-27
诺诚健华:公司应收账款与药品销售收入相匹配
“止血”扭亏为盈后,诺诚健华的“造血”硬仗才刚开打
东方财富网 · 10-27
“止血”扭亏为盈后,诺诚健华的“造血”硬仗才刚开打
加载更多
公司概况
公司名称:
诺诚健华医药有限公司
所属行业:
医药制造业
上市日期:
2022-09-21
主营业务:
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗及mesutoclax。
发行价格:
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":24.13,"timestamp":1794812400000,"preClose":24.99,"halted":0,"volume":6751472,"delay":0,"changeRate":-0.0344,"floatShares":273000000,"shares":1770000000,"eps":0.77,"marketStatus":"已收盘","change":-0.86,"latestTime":"11-16 15:00:00","open":25.54,"high":25.58,"low":24.01,"amount":165000000,"amplitude":0.0628,"askPrice":24.14,"askSize":14,"bidPrice":24.13,"bidSize":67,"shortable":0,"etf":0,"ttmEps":0.77,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794879000000},"marketStatusCode":5,"adr":0,"adjPreClose":24.99,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794792600000,1794799800000],[1794805200000,1794812400000]],"highLimit":27.49,"lowLimit":22.49,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1769688139,"isCdr":false,"pbRate":5.21,"roa":"--","peRate":31.337662,"roe":"8.25%","epsLYR":0.38,"committee":0.387097,"marketValue":42703000000,"turnoverRate":0.0247,"status":1,"afterMarket":{"amount":69060.06,"volume":2862,"close":24.13,"buyVolume":0,"sellVolume":3838,"time":1794814437746,"indexStatus":"已收盘 11-16 15:30:00","preClose":24.99},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":11.27,"timestamp":1794816493010,"preClose":11.61,"halted":0,"volume":4625744,"delay":0,"premium":"-60.32"},"floatMarketCap":6597000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2683566666","title":"诺诚健华(688428.SH):佐来曲替尼片纳入2026年国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683566666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683566666?lang=zh_cn&edition=full","pubTime":"2026-11-15 17:03","pubTimestamp":1794733381,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺诚健华(688428.SH)发布公告,公司自主研发的新一代TRK抑制剂佐来曲替尼片(商品名:宜诺欣®)被纳入新版国家医保目录,用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者。新版国家医保目录将自2027年1月1日起正式实施。协议有效期为2027年1月1日至2028年12月31日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1161","BK1574","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683656366","title":"诺诚健华:佐来曲替尼纳入2026年国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683656366","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683656366?lang=zh_cn&edition=full","pubTime":"2026-11-15 16:53","pubTimestamp":1794732816,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688428","BK1574","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683359680","title":"诺诚健华广谱抗癌药宜诺欣纳入2026年国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683359680","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683359680?lang=zh_cn&edition=full","pubTime":"2026-11-14 14:05","pubTimestamp":1794636341,"startTime":"0","endTime":"0","summary":"11月14日,2026年《国家基本医疗保险、生育保险和工伤保险药品目录》发布,诺诚健华自主研发的新一代TRK抑制剂宜诺欣?(佐来曲替尼)被纳入新版国家医保药品目录,用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者。2025年12月,佐来曲替尼获批治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者,是中国首个自主研发获批上市的新一代TRK抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611143931331385.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611143931331385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","09969","BK0239","CANC","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683519714","title":"股市必读:诺诚健华(688428)11月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2683519714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683519714?lang=zh_cn&edition=full","pubTime":"2026-11-13 02:21","pubTimestamp":1794507671,"startTime":"0","endTime":"0","summary":"截至2026年11月12日收盘,诺诚健华报收于25.99元,上涨0.27%,换手率2.12%,成交量5.81万手,成交额1.52亿元。董秘最新回复投资者: 请问公司最新一期的股东户数是多少?截止到2026年10月30日公司A股股东户数约为2.1万户。公司尚未向上述机构进行捐赠或开展合作。当日关注点交易信息汇总:11月12日主力资金净流出551.25万元,占总成交额3.63%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300002386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","09969","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682909566","title":"诺诚健华:公司尚未向上述机构进行捐赠或开展合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2682909566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682909566?lang=zh_cn&edition=full","pubTime":"2026-11-12 17:33","pubTimestamp":1794475989,"startTime":"0","endTime":"0","summary":"证券之星消息,诺诚健华(688428)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,想咨询一下董事长兼总经理Jisong Cui(崔霁松)的毕业院校,公司是否曾向其母校捐赠、与其共建实验室等公益安排或校企合作?诺诚健华回复:尊敬的投资者,您好!Jisong Cui(崔霁松)博士曾就读于山东大学、普渡大学,并在霍华德·休斯医学研究所从事博士后研究。公司尚未向上述机构进行捐赠或开展合作。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200031125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682566913","title":"诺诚健华:截止到2026年10月30日公司A股股东户数约为2.1万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2682566913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682566913?lang=zh_cn&edition=full","pubTime":"2026-11-12 17:33","pubTimestamp":1794475988,"startTime":"0","endTime":"0","summary":"证券之星消息,诺诚健华(688428)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司最新一期的股东户数是多少?谢谢诺诚健华回复:尊敬的投资者,您好!截止到2026年10月30日公司A股股东户数约为2.1万户。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200031126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03130","07233","02843","399300","83130","82823","09969","BK1161","03188","02846","82846","BK1574","BK1147","02827","BK1610","82843","159982","688428","BK0239","82822","02823","83188","02822"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682328438","title":"诺诚健华(688428)11月10日主力资金净卖出633.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682328438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682328438?lang=zh_cn&edition=full","pubTime":"2026-11-11 08:34","pubTimestamp":1794357299,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月10日收盘,诺诚健华报收于26.2元,下跌0.91%,换手率2.16%,成交量5.9万手,成交额1.56亿元。近5日资金流向一览见下表:诺诚健华融资融券信息显示,融资方面,当日融资买入1081.02万元,融资偿还1021.26万元,融资净买入59.75万元。诺诚健华主营业务:主要从事生物医药研发、生产和商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100013620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681578097","title":"诺诚健华(688428)11月4日主力资金净卖出1159.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681578097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681578097?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:27","pubTimestamp":1793838466,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月4日收盘,诺诚健华报收于26.05元,上涨9.78%,换手率6.18%,成交量16.91万手,成交额4.26亿元。近5日资金流向一览见下表:诺诚健华融资融券信息显示,融资方面,当日融资买入2062.88万元,融资偿还2671.26万元,融资净偿还608.37万元。诺诚健华主营业务:主要从事生物医药研发、生产和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500009828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","BK1161","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680367470","title":"11月4日诺诚健华涨9.78%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680367470","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680367470?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:19","pubTimestamp":1793783961,"startTime":"0","endTime":"0","summary":"证券之星消息,11月4日诺诚健华涨9.78%,收盘报26.05元,换手率6.18%,成交量16.91万手,成交额4.26亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共26家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为30.0亿元,最新净值2.8021,较上一交易日下跌1.69%,近一年下跌17.01%。富国精准医疗混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680036721","title":"诺诚健华涨9.78%,长城国瑞证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680036721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680036721?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:19","pubTimestamp":1793783951,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨9.78%,收盘报26.05元。2026年8月31日,长城国瑞证券研究员胡晨曦发布了对诺诚健华的研报《药品收入持续高增,自免管线兑现在即》,该研报对诺诚健华给出“买入”评级。因此,我们维持其“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680206708","title":"诺诚健华企业传播执行总监陆春华:商业化是压舱石 全球化是必答题","url":"https://stock-news.laohu8.com/highlight/detail?id=2680206708","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680206708?lang=zh_cn&edition=full","pubTime":"2026-11-01 17:07","pubTimestamp":1793524020,"startTime":"0","endTime":"0","summary":"“全球化是必答题,不是选择题。”10月30日,由《证券日报》社主办的“大国新药价值重构——2026大健康产业大会”在杭州举行。在以“资本赋能创新医药——从估值到价值的突围”为主题的圆桌论坛环节,北京诺诚健华医药科技有限公司(以下简称“诺诚健华”)企业传播执行总监陆春华围绕创新药企从研发价值走向商业价值、从国内市场走向全球舞台的路径分享了经验与判断。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611013917726647.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611013917726647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","BK0239","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679252355","title":"大行评级|招银国际:微升诺诚健华目标价至18.9港元,维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2679252355","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679252355?lang=zh_cn&edition=full","pubTime":"2026-10-30 10:27","pubTimestamp":1793327251,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK1574","09969","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678555054","title":"高盛:上调诺诚健华(09969)目标价至23.16港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2678555054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678555054?lang=zh_cn&edition=full","pubTime":"2026-10-28 15:30","pubTimestamp":1793172636,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,高盛发布研报称,诺诚健华第三季总收入高于该行预期,该行将H股12个月目标价由22.71港元上调至23.16港元,诺诚健华A股目标价由37.93元人民币上调至38.68元人民币,评级“买入”。诺诚健华今年第三季药物销售5.31亿元人民币(下同),同比升39%,大致符合该行预期的5.48亿元,主要受奥布替尼持续放量带动,包括一线CLL/SLL纳入国家医保目录后的贡献,以及MZL的差异化贡献。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678439972","title":"港股异动 | 诺诚健华(09969)涨超4% 前三季度实现扭亏为盈 核心产品奥布替尼持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2678439972","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678439972?lang=zh_cn&edition=full","pubTime":"2026-10-28 11:26","pubTimestamp":1793157973,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,诺诚健华涨超4%,截至发稿,涨5.08%,报14.49港元,成交额3486.42万港元。消息面上,近日,诺诚健华公布2026年前三季度业绩,公司总营业收入为20.99亿元,比上年同期增长88.21%,其中药品销售收入为14.49亿元,比上年同期增长 41.47%。营业收入增长主要原因为核心产品奥布替尼持续放量、坦昔妥单抗和佐来曲替尼新增销售贡献以及公司与Zenas BioPharma,Inc.的授权许可协议完成后续里程碑交付。归属于上市公司股东的净利润约6.56亿元,同比扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","688428","BK0239","BK4585","BK4588","BK1574","VXUS","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678435644","title":"诺诚健华Q3营收大增150.60%:BD里程碑收入推高业绩,奥布替尼独挑商业化大梁","url":"https://stock-news.laohu8.com/highlight/detail?id=2678435644","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678435644?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:02","pubTimestamp":1793152948,"startTime":"0","endTime":"0","summary":"本文来源:时代周报作者:曹予韩迅诺诚健华(688428.SH/09969.HK)第三季度营业收入同比大增150.60%。但同期药品销售收入增速为38.59%。两组数据出现明显剪刀差,内生盈利能力引发市场关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283911363089.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283911363089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678883204","title":"股市必读:诺诚健华三季报 - 第三季度单季净利润同比增长1292.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678883204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678883204?lang=zh_cn&edition=full","pubTime":"2026-10-28 03:55","pubTimestamp":1793130909,"startTime":"0","endTime":"0","summary":"截至2026年10月27日收盘,诺诚健华报收于25.16元,下跌2.25%,换手率4.69%,成交量12.82万手,成交额3.31亿元。业绩披露要点:2026年前三季度归母净利润6.56亿元,同比上升1117.93%;第三季度单季度归母净利润4.09亿元,同比上升1292.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800004018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678917232","title":"诺诚健华:10月27日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2678917232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678917232?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:01","pubTimestamp":1793102475,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年10月27日诺诚健华发布公告称公司于2026年10月27日召开业绩说明会。相关对外引进事项尚存在不确定性,请投资者注意投资风险。根据公司季度报告,2026年第三季度公司营业收入9.62亿元,其中药品销售收入5.31亿元,其余营业收入主要为公司与Zenas达成的独家许可协议所实现的里程碑收入。公司与 Zenas 的合作项目正按协议计划稳步推进,2026年第四季度及2027年,协议项下存在若干临床开发节点具备里程碑触发的潜在可能性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700038250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","688428","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678352120","title":"诺诚健华:截止到2026年9月30日公司A股股东户数约为2.1万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2678352120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678352120?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:54","pubTimestamp":1793094858,"startTime":"0","endTime":"0","summary":"证券之星消息,诺诚健华(688428)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问:您好!请问截至9月底公司股东人数是多少,谢谢!诺诚健华回复:尊敬的投资者,您好!截止到2026年9月30日公司A股股东户数约为2.1万户。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700033154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["82822","02827","83188","82823","82846","02843","159982","07233","03130","03188","02822","02846","82843","83130","BK1161","399300","BK1147","688428","BK1574","02823","09969","BK1610","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678120866","title":"诺诚健华:公司应收账款与药品销售收入相匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2678120866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678120866?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:54","pubTimestamp":1793094848,"startTime":"0","endTime":"0","summary":"证券之星消息,诺诚健华(688428)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,首先祝贺下公司取得不错的业绩,但是我们也看到公司的应收账款远低于药品销售收入,造成这些的原因是哪些?如何改善?诺诚健华回复:尊敬的投资者,您好!公司应收账款与药品销售收入相匹配,公司应收账款结构良好,坏账风险低,回款周期正常。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700033146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09969","BK0239","688428","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678245801","title":"“止血”扭亏为盈后,诺诚健华的“造血”硬仗才刚开打","url":"https://stock-news.laohu8.com/highlight/detail?id=2678245801","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678245801?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:52","pubTimestamp":1793091168,"startTime":"0","endTime":"0","summary":"蓝鲸新闻10月27日讯(记者何天骄)2026年三季报,诺诚健华(688428.SH/09969.HK)交出一份“扭亏+翻倍增长”的答卷:前三季度营收20.99亿元,同比增长88.21%;药品销售14.49亿元,同比增长41.47%;净利润6.48亿元,去年同期为亏损0.72亿元;达到2.2亿元,同比由负转正。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610273909931718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610273909931718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK1161","09969","BK1574","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794834594315,"stockEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.04},{"period":"3month","weight":-0.2171},{"period":"6month","weight":-0.0075},{"period":"1year","weight":-0.0072},{"period":"ytd","weight":0.2178}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21000人(较上一季度增加0.00%)","perCapita":"13019股","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗及mesutoclax。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}